Why would the FDA make such an outrageous decision to enter into an unprecedented agreement to monitor post-marketing drug surveillance with a private company run by ex-pharmaceutical executives? The FDA would be better off looking at its FAERS data. If they did, they would see drug signals that they have ignored, especially for FQ’s.
Do we welcome an organization into our midst that; employs former pharmaceutical execs? Sponsors events attended by pharmaceutical companies? Most of which have connections to Fluoroquinolones?